Retatrutide Before and After: What the Clinical Data Shows
Last updated: March 2026
Retatrutide Phase 2 data shows participants lost an average of 24.2% of body weight at the highest dose (12mg) over 48 weeks — roughly 58 lbs for a 240-lb person — with no plateau observed, suggesting even greater loss with longer treatment.
Real weight loss results from the Phase 2 trial of retatrutide (LY3437943) — the triple-agonist that produced up to 24.2% body weight loss in 48 weeks.
📋 On this page
- Retatrutide Weight Loss by Dose
- How Fast Does Retatrutide Work?
- What Retatrutide Results Look Like in Real Weight
- Retatrutide vs. Tirzepatide vs. Semaglutide
- Fat Loss vs. Lean Mass
- Most Common Adverse Events
- Retatrutide Weight Loss Timeline
- Retatrutide Before and After — The Bottom Line
- Essential Tools for Weight Loss Tracking
- Mental Clarity, Cognition & Inflammation
- Related Research & Tools
- Frequently Asked Questions
Retatrutide Weight Loss by Dose
Percent change in body weight at 48 weeks across all dose groups. Data from the Phase 2 trial (NCT04881760).
How Fast Does Retatrutide Work?
Percent body weight change at key timepoints (24 and 48 weeks) across dose groups. These are the reported timepoints from the Phase 2 trial.
Note: Approximate 24-week values read from published trial figures. Exact interim timepoints beyond 24 and 48 weeks were not separately reported in the primary publication.
What Retatrutide Results Look Like in Real Weight
Based on trial averages applied to an example starting weight of 220 lbs (100 kg). Individual results vary.
| Dose Group | % Lost at 24 wk | Weight at 24 wk | % Lost at 48 wk | Weight at 48 wk | Total lbs Lost |
|---|---|---|---|---|---|
| Placebo | −2.0% | 215.6 lbs | −2.1% | 215.4 lbs | 4.6 lbs |
| 1 mg | −6.0% | 206.8 lbs | −8.7% | 200.9 lbs | 19.1 lbs |
| 4 mg (escalated) | −11.0% | 195.8 lbs | −17.1% | 182.4 lbs | 37.6 lbs |
| 4 mg (fixed) | — | — | −12.9% | 191.6 lbs | 28.4 lbs |
| 8 mg | −17.0% | 182.6 lbs | −22.8% | 169.8 lbs | 50.2 lbs |
| 12 mg | −19.0% | 178.2 lbs | −24.2% | 166.8 lbs | 53.2 lbs |
Starting weight: 220 lbs (100 kg). "Weight at X wk" = 220 × (1 − % lost). These are averages — individual results vary significantly.
Retatrutide vs. Tirzepatide vs. Semaglutide
Peak weight loss across three landmark clinical trials. Different study durations — see caveat below.
Fat Loss vs. Lean Mass
The Phase 2 trial reported that the majority of weight lost was fat mass. Detailed body composition data from the highest-dose groups:
Body composition was assessed as a secondary endpoint. The fat-to-lean mass loss ratio is consistent with other GLP-1 receptor agonist trials. Detailed sub-group breakdowns were limited in the Phase 2 publication. Resistance training during weight loss can help preserve lean mass.
Most Common Adverse Events
Reported in the 12 mg dose group. Most side effects were mild-to-moderate and decreased over time with dose escalation.
Approximate percentages from the 12 mg escalated dose group. Gastrointestinal events were the most common reason for discontinuation. Dose escalation schedules reduced GI side effect severity.
Retatrutide Weight Loss Timeline
General phases observed in the clinical trial, based on the weight loss trajectory in the higher-dose groups.
Retatrutide Before and After — The Bottom Line
✅ What We Know
- The 12 mg dose produced 24.2% mean body weight loss in 48 weeks — the highest ever reported for an obesity drug at the time
- Clear dose-response: higher doses produced more weight loss
- Weight was still declining at 48 weeks (the study hadn't plateaued)
- Majority of weight lost (~78%) was fat mass, not lean mass
- GI side effects are common but mostly mild-to-moderate and improve over time
- Triple-agonist mechanism (GIP + GLP-1 + Glucagon) differentiates it from existing drugs
- Phase 3 trials (TRIUMPH program) are underway for more definitive data
⚠️ What We Don't Know
- Long-term safety beyond 48 weeks is unproven — Phase 3 trials are ongoing
- What happens after discontinuation (weight regain is expected based on other GLP-1 drugs)
- Cardiovascular outcomes data (no CVOT completed yet)
- How it compares head-to-head vs tirzepatide or semaglutide
- Optimal dosing — the 8 mg and 12 mg groups had similar GI side effect rates
- Effects on specific populations (no data on older adults, T2D-specific outcomes, etc.)
- FDA approval timeline — still investigational, not approved for any indication
Essential Tools for Weight Loss Tracking
Tracking your weight, body composition, and meals is critical for anyone on a weight loss journey.
Affiliate links help support HighPeptides at no extra cost to you.
Mental Clarity, Cognition & Inflammation
Beyond fat loss, retatrutide users frequently report sharper focus and less inflammatory "stiffness." Here is the receptor-level mechanism — and exactly where the evidence stops.
Cognition. GLP-1 receptors are expressed in the hippocampus and prefrontal cortex — the regions behind memory and executive focus. In the phase 2b ELAD trial, liraglutide did not change the primary endpoint of cerebral glucose metabolism in Alzheimer's patients, but a secondary executive-function score (ADAS-Exec) favored liraglutide over placebo (Edison 2026, PMID 41326666), and in Parkinson's the Exenatide-PD trial found exenatide preserved off-medication motor function (Athauda 2017, PMID 28781108). Retatrutide adds GIP and glucagon receptor activity — both neurotrophic in preclinical models — so the sharper focus and reduced "brain fog" users describe has a plausible receptor basis, though no retatrutide-specific cognition trial exists yet.
Inflammation. In preclinical models, GLP-1 / GIP dual agonists reduced neuroinflammation and oxidative stress and protected synaptic numbers and synaptic activity (Hölscher review, PMID 29402504). Systemically, much of the anti-inflammatory benefit is downstream of fat loss itself: visceral adipose tissue is a primary source of IL-6 and TNF-α, and retatrutide reduces fat mass harder than any GLP-1 to date — a least-squares mean 24.2% reduction in body weight at 48 weeks in the highest-dose (12 mg) arm of the phase 2 obesity trial (Jastreboff 2023, PMID 37366315). Less adipose mass means less inflammatory signaling.
Related Research & Tools
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
Research-Grade Peptides
Third-party tested compounds with certificates of analysis. Used by researchers worldwide.
Affiliate link — supports HighPeptides at no extra cost.
Disclaimer: This page is for educational and informational purposes only. It is not medical advice. Retatrutide (LY3437943) is an investigational drug not approved by the FDA. "Before and after" data represents clinical trial averages — individual results vary significantly. Always consult with a qualified healthcare provider. Data sourced from Jastreboff et al., N Engl J Med 2023; 389:514-526. ClinicalTrials.gov: NCT04881760.
Frequently Asked Questions
What does retatrutide weight loss look like?
Phase 2 clinical trial data shows that participants on retatrutide 12mg lost an average of 24.2% of their body weight over 48 weeks — translating to roughly 58 lbs for a 240-lb person. The weight loss was progressive, continuing throughout the trial without plateauing, which is unusual compared to other obesity medications.
How fast do you lose weight on retatrutide?
In Phase 2 trials, weight loss began within the first 4 weeks and continued progressively throughout the 48-week study period. Participants at the 12mg dose lost approximately 2–3% of body weight per month during peak treatment. Unlike some other GLP-1 drugs, retatrutide's weight loss curve showed no significant plateau by week 48, suggesting continued loss with longer treatment.
Is retatrutide better than semaglutide?
Based on Phase 2 clinical data, retatrutide produced significantly greater weight loss (24.2%) than semaglutide (approximately 14.9% in comparable trials) — roughly 60% more weight loss. Retatrutide's triple agonist mechanism (GIP/GLP-1/Glucagon) appears more powerful than semaglutide's single GLP-1 mechanism. However, head-to-head trials have not been conducted, and retatrutide is not yet FDA-approved.